Amedica Corporation, a biomaterial company, develops, manufactures, and commercializes a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. The company offers silicon nitride implants to surgeons and hospitals for use in cervical and thoracolumbar spine surgery under the Valeo brand. It also provides a line of non-silicon nitride spinal fixation products to address spinal deformity and degenerative conditions. The company markets and sells its products directly; and through a network of independent sales distributors, as well original equipment manufacturer and private label partnerships. Amedica Corporation was founded in 1996 and is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AMDA
CUSIPN/A
Phone801-839-3500
Debt
Debt-to-Equity RatioN/A
Current Ratio1.11
Quick Ratio0.99
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$11.22 million
Price / Sales0.26
Cash FlowN/A
Price / CashN/A
Book Value$1.80 per share
Price / Book0.14
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-9,320,000.00
Net Margins-139.55%
Return on Equity-148.64%
Return on Assets-67.84%
Miscellaneous
Employees33
Outstanding Shares11,870,000
Market Cap$3.10 million
Amedica (NASDAQ:AMDA) Frequently Asked Questions
What is Amedica's stock symbol?
Amedica trades on the NASDAQ under the ticker symbol "AMDA."
When did Amedica's stock split? How did Amedica's stock split work?
Amedica shares reverse split on the morning of Friday, November 10th 2017. The 1-12 reverse split was announced on Friday, November 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 9th 2017. An investor that had 100 shares of Amedica stock prior to the reverse split would have 8 shares after the split.
How were Amedica's earnings last quarter?
Amedica Co. (NASDAQ:AMDA) announced its quarterly earnings results on Tuesday, November, 21st. The medical equipment provider reported ($0.93) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.94) by $0.01. The medical equipment provider had revenue of $2.96 million for the quarter. Amedica had a negative net margin of 139.55% and a negative return on equity of 148.64%. View Amedica's Earnings History.
When is Amedica's next earnings date?
What is the consensus analysts' recommendation for Amedica?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedica in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amedica.
Are investors shorting Amedica?
Amedica saw a increase in short interest in August. As of August 31st, there was short interest totalling 729,652 shares, an increase of 29.8% from the August 15th total of 562,336 shares. Based on an average trading volume of 745,214 shares, the short-interest ratio is currently 1.0 days. Currently, 6.1% of the shares of the stock are short sold. View Amedica's Current Options Chain.
Who are some of Amedica's key competitors?
Some companies that are related to Amedica include Alliqua Biomedical (ALQA), Neurometrix (NURO), Regenicin (RGIN), Atossa Genetics (ATOS), Viatar CTC Solutions (VRTT), United American Healthcare (UAHC), Cytocore (MDIT), Delcath Systems (DCTH), Encision (ECIA), Calmare Therapeutics (CTTC), Cytori Therapeutics (CYTX), Delcath Systems (DCTHD), TearLab (TEAR), AdvanSource Biomaterials Corpration (ASNB) and OxySure Therapeutics (OXYS).
Who are Amedica's key executives?
Amedica's management team includes the folowing people:
- Dr. B. Sonny Bal, Chairman, CEO, Pres & Principal Financial Officer (Age 56)
- Mr. Bryan J. McEntire, Chief Technology Officer (Age 66)
- Mr. David O'brien, GM & VP Operations
- Mr. Dana Lyons, VP of Sales & Marketing
Has Amedica been receiving favorable news coverage?
News coverage about AMDA stock has been trending somewhat positive on Thursday, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amedica earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Amedica.
Who are Amedica's major shareholders?
Which major investors are buying Amedica stock?
How do I buy shares of Amedica?
Shares of AMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amedica's stock price today?
One share of AMDA stock can currently be purchased for approximately $0.25.
How big of a company is Amedica?
Amedica has a market capitalization of $3.10 million and generates $11.22 million in revenue each year. Amedica employs 33 workers across the globe.
How can I contact Amedica?
Amedica's mailing address is 1885 WEST 2100 SOUTH, SALT LAKE CITY UT, 84119. The medical equipment provider can be reached via phone at 801-839-3500 or via email at [email protected]
MarketBeat Community Rating for Amedica (NASDAQ AMDA)
MarketBeat's community ratings are surveys of what our community members think about Amedica and other stocks. Vote "Outperform" if you believe AMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
